HOME
>
臨床医学：内科
>
老人医学
> 睡眠からみた認知症診療ハンドブック

睡眠からみた認知症診療ハンドブック

出版社：	全日本病院出版会
著者：	宮崎総一郎浦上克哉(編)
発行日：	2016-09-20
分野：	臨床医学：内科 > 老人医学
ISBN：	9784865192193
電子書籍版：	2016-09-20 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

3,850 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

3,850 円(税込)

購入する

商品紹介

認知症や脳疾患の予防には脳の役割を知り、適切な睡眠を確保することが重要であり、睡眠の観点から認知症予防と診療に重点をおいてまとめられた１冊！

目次

睡眠からみた認知症診療ハンドブック

―目次―

I 総　論
　１．睡眠とは
　２．認知症とは
　３．健やかに老いるための時間老年学
　４．認知症の基礎研究

II 各　論
　１．睡眠障害と認知症
　２．睡眠呼吸障害と認知症
　３．昼寝と認知症
　４．光と認知症
　５．聴力低下と認知症
　６．においと睡眠

III 診　断
　１．認知症の早期診断
　２．認知症の嗅覚検査
　３．嗅覚障害からみた認知症早期診
　４．認知症の臨床検査
　５．アルツハイマー型認知症のバイオマーカー

IV 治　療
　１．認知症の治療総論
　２．睡眠衛生指導―地域におけるSleep health promotionと
　　　　施設での睡眠マネジメント―
　３．薬物療法
　４．運動による認知症予防
　５．口腔衛生と認知症予防

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.7 掲載の参考文献

1) 宮崎総一郎 : 睡眠と健康 : 8, 放送大学教育振興会. 2013.

2) NHK放送文化研究所 : 2015年国民生活時間報告書, NHK放送文化研究所 (http://www.nhk.or.jp/bunken/research/yoron/pdf/20160217_1.pdf)

3) Tamakoshi A, et al : Self-reported sleep duration as a predictor of all-cause mortality : results from the JACC study, Japan. Sleep, 27 : 51-54, 2004.

4) Gangwisch JE, et al : Short sleep duration as a risk factor for hypertension : analyses of the first National Health and Nutrition Examination Survey. Hypertension, 47 : 833-839, 2006.

5) Ohayon MM, et al : Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals : developing normative sleep values across the human lifespan. Sleep, 27 : 1255-1273, 2004.

6) Hirschkowitz M, et al : National Sleep Foundation's sleep time duration recommendations : methodology and results summary. Sleep Health, 1 : 40-43, 2015.

7) Nedergaard M : Garbage truck of the brain. Science, 340 : 1529-1530, 2013.

8) Xie L, et al : Sleep drives metabolite clearance from the adult brain. Science, 342 : 373-377, 2013.

9) Walker M, et al : Practice with sleep makes perfect : sleep-dependent motor skill learning. Neuron, 35 : 205-211, 2002.

10) Plihal W, et al : Effects of early and late nocturnal sleep on declarative and procedural memory. J Cogn Neurosci, 9 : 534-547, 1997.

11) Yo-El SJ, et al : Sleep quality and preclinical Alzhemer disease. JAMA Neurol, 70 : 587-593, 2013.

12) Spira AP, et al : Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol, 70 : 1537-1543, 2013.

13) Ooms S, et al : Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle aged men : a randomized clinical trial. JAMA Neurol, 71 : 971-977, 2014.

P.9 掲載の参考文献

1) Petersen R, et al : Mild cognitive impairment ; Clinical characterization and outcome. Arch Neurol, 56 : 303-308, 1999.

2) Winblad B, et al : Mild cognitive impairment ; Beyond controversies, towards a concensus-Report of the International Working Group on mild cognitive impairment. J Intern Med, 256 : 240-246, 2004.

3) 浦上克哉 : 専門医はMCIをこうとらえている-双方向セッション-. 老精医誌, 20 (増刊号) : 30-34, 2009.

4) McKhann GM, et al : The diagnosis of dementia due to Alzheimer's disease : Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's & Dementia, 2011 : 1-7, 2011.

5) Albert MS, et al : The diagnosis of mild cognitive impairment due to Alzheimer's disease : Recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimer's & Dementia, 2011 : 1-10, 2011.

6) Sperling RA, et al : Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's & Dementia, 2011 : 1-13, 2011.

P.15 掲載の参考文献

1) Castanon-Cervantes O, et al : Dysregulation of inflammatory responses by chronic circadian disruption. J Immunol, 185 : 5796-5805, 2010.

2) Mavroudis PD, et al : Systems biology of circadian-immune interactions. J Innate Immun, 5 : 153-162, 2013.

3) Scheiermann C, et al : Circadian control of the immune system. Nat Rev Immunol, 13 : 190-198, 2013.

4) 大塚邦明 : 時間内科学 : 325, 中山書店, 2013.

5) 大塚邦明 : 健やかに老いるための時間老年学 : 261, ミシマ社, 2014.

6) 大塚邦明 : 時間医学とこころの時計 : 231, 清流出版, 2015.

7) Konopka RJ, et al : Clock mutants of Drosophila melanogaster. Proc Natl Acad Sci USA, 68 : 2112-2116, 1971.

8) Hastings M, et al : Circadian clocks : regulators of endocrine and metabolic rhythms. J Endocrinol, 195 : 187-198, 2007.

9) Hirayama J, et al : CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature, 450 : 1086-1090, 2007.

10) Imai S, et al : Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 403 : 795-800, 2000.

11) Nakahata Y, et al : The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell, 134 : 329-340, 2008.

12) Belden, et al : SIRT1 is a circadian deacetylase for core clock components. Cell, 134 : 212-214, 2008.

13) Kondratov RV, et al : Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock. Genes & Development, 20 : 1868-1873, 2006.

14) Froy O : Circadian rhythms, aging, and life span in mammals. Physiology, 26 : 225-235, 2011.

15) Oster H, et al : Loss of circadian rhythmicity in aging mPer1-/1 mCry2-/-mutant mice. Genes Dev, 17 : 1366-1379, 2003.

16) Zhang Y, et al : Effects of aging on lens transmittance and retinal input to the suprachiasmatic nucleus in golden hamsters. Neurosci Lett, 258 : 167-170, 1998.

17) 寺北明久 : 概日リズムの光同調に関わる光受容タンパク質メラノプシン. 時間生物学, 14 : 21-28, 2008.

18) Froy O : Metabolism and circadian rhythms : implications for obesity. Endocr Rev, 31 : 1-24, 2010.

19) Yang X, et al : Nuclear receptor expression links the circadian clock to metabolism. Cell, 126 : 801-810, 2006.

20) Zvonic S, et al : Characterization of peripheral circadian clocks in adipose tissues. Diabetes, 55 : 962-970, 2006.

21) Prosser RA, et al : Leptin phase-advances the rat suprachiasmatic circadian clock in vitro. Neurosci Lett, 336 : 139-142, 2003.

22) Yannielli PC, et al : Ghrelin effects on the circadian system of mice. J Neurosci, 27 : 2890-2895, 2007.

23) Turek FW, et al : Obesity and metabolic syndrome in circadian Clock mutant mice. Science 308 : 1043-1045, 2005.

24) Rudic RD, et al : BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol, 2 : e377, 2004.

25) Lamia KA, et al : Physiological significance of a peripheral tissue circadian clock. Proc Natl Acad Sci USA, 105 : 15172-15177, 2008.

26) Anisimov VN, et al : Metformin slows down aging and extends life span of female SHR mice. Cell Cycle, 7 : 2769-2773, 2008.

27) Wood JG, et al : Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 43 : 686-689, 2004.

28) Harrison DE, et al : Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460 : 392-395, 2009.

29) Scheer FAJL, et al : Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension, 43 : 192-197, 2004.

P.25 掲載の参考文献

1) Dementia in the Asia Pacific Region : Alzheimer's Disease International Report 2014, Alzheimer's Disease International, London, 2014.

2) Dementia warning for the Asia-Pacific region. Lancet Neurology, 14 : 1, 2015.

3) Ferri CP, et al : Global prevalence of dementia : a Delphi consensus study. Lancet, 366 : 2112-2117, 2005.

4) 朝田隆 : 厚生労働科学研究費補助金認知症対策総合研究事業報告書「都市部における認知症有病率と認知症の生活機能障害への対応」, 2013年3月.

5) 厚生労働省HP : 認知症の人の将来推計について (http://www.mhlw.go.jp/stf/houdou/0000072246.html)

6) Ikejima C, et al : Multicentre population-based dementia prevalence survey in Japan : a preliminary report. Psychogeriatrics, 12 : 120-123, 2012.

7) Engelhardt E, et al : Alzheimer's 100th anniversary of death and his contribution to a better understanding of Senile dementia. Arq Neuropsiquiatr, 73 : 159-162, 2015.

8) Alzheimer A : Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und phychish-Gerichtliche Medizin, 64 : 146-148, 1907.

9) Braak H, et al : Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol Aging, 15 : 355-356, 1994.

10) Braak H, et al : Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog Brain Res, 117 : 267-285, 1998.

11) Nunan J, et al : Regulation of APP cleavage by alpha-, beta-and gamma-secretases. FEBS Lett, 483 : 6-10, 2000.

12) Selkoe DJ, et al : Presenilin : running with scissors in the membrane. Cell, 131 : 215-221, 2007.

13) McLean RA, et al : Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol, 46 : 860-866, 1999.

14) Wang J, et al : The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol, 158 : 328-337, 1999.

15) Naslund J, et al : Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA, 283 : 1571-1577, 2000.

16) Ferreira ST, et al : The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem, 96 : 529-543, 2011.

17) Cleary JP, et al : Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci, 8 : 79-84, 2005.

18) Butterfield DA, et al : The critical role of methionine 35 in Alzheimer's amyloid β-peptide (1-42) -induced oxidative stress and neurotoxicity. Biochim Biophys Acta, 1703 : 149-156, 2005.

19) Butterfield DA, et al : Amyloid beta-peptide (1-42) -induced oxidative stress in Alzheimer disease : importance in disease pathogenesis and progression. Antioxid Redox Signal, 19 : 823-835, 2013.

20) 井原康夫 : 日頃疑問に思うことなど (第28回日本認知症学会学術集会キーノートレクチャー). Dementia Japan, 24 : 1-9, 2010.

21) Noble W, et al : The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol, 4 : a83, 2013.

22) Mandelkow E-M, et al : Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med, 2 : a006247, 2012.

23) Braak H, et al : Neuropathological staging of Alzhemer-related changes. Acta Neuroptahol, 82 : 239-259, 1991.

24) Giraldo E, et al : Abeta and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation : protective role of vitamin E. Redox Biol, 2 : 873-877, 2014.

25) Lloret A, et al : Amyloid-beta toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis, 27 : 701-709, 2011.

26) Lloret A, et al : Molecular mechanisms linking amyloid beta toxicity and Tau hyperphosphorylation in Alzheimer's disease. Free Radic Biol Med, 83 : 186-191, 2015.

27) Francis PT, et al : The cholinergic hypothesis of Alzheimer's disease : a review of progress. J Neurol Neurosurg Psychiatry, 66 : 137-147, 1999.

28) Goate AM, et al : Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 349 : 704-706, 1991.

29) Hardy JA, et al : Alzheimer's disease : the amyloid cascade hypothesis. Science, 256 : 184-185, 1992.

30) Sherrington R, et al : Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature, 375 : 754-760, 1995.

31) Levy-Lahad A, et al : Candidate gene for the chromosome 1 familiar Alzheimer's disease locus. Science, 269 : 973-976, 1995.

32) Selkoe DJ, et al : In search of gamma-secretase : presenilin at the cutting edge. Proc Natl Acad Sci USA, 97 : 5690-5692, 2000.

33) Jonsson T, et al : A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature, 488 : 96-99, 2012.

34) Tomiyama T, et al : A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol, 63 : 377-387, 2008.

35) 荒井啓行ほか : アルツハイマー病の病態とバイオマーカー開発. 日薬理誌, 135 : 3-7, 2010.

36) Sperling RA, et al : Towards defining the preclinical stages of Alzhimer's disease : recommendation from the National Institute on Aging-Alzheimer's Association workgroup on diagnostic guidelines for Alzheimer's disease. Alzheimer Dement, 7 : 280-292, 2011.

37) Bateman RJ, et al : Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 367 : 795-804, 2012.

38) Weiner MW, et al : The Alzheimer's Disease Neuroimaging Initiative : A review of papers published since its inception. Alzheimers Dement, 9 (5) : e111-194, 2013.

39) Amariglio RE, et al : Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly. Neurology, 85 : 56-62, 2015.

40) Rowe CC, et al : Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging, 31 : 1275-1283, 2010.

41) McKhann GM, et al : The diagnosis of dementia due to Alzheimer's disease : recommendation from the National Institute on Aging-Alzheimer's Association workgroup on diagnostic guidelines for Alzheimer's disease. Alzheimer Dement, 7 : 263-269, 2011.

42) 岩田淳ほか : アルツハイマー病の新しい診断ガイドラインオーバービュー. Dementia Japa, 27 : 307-315, 2013.

43) 嶋田裕之 : 画像診断新しい診断ガイドライン. Dementia Japan, 27 : 324-333, 2013.

44) Maruyama M, et al : Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron, 79 : 1094-1108, 2013.

45) Okamura N, et al : Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain, 137 : 1762-1771, 2014.

46) Sparing RA, et al : The A4 study : stopping AD before symptoms begin-Sci Transl Med, 6 : 228fs13, 2014.

47) Mills SM, et al : Preclinical trials in autosomal dominant AD : implementation of the DIAN-TU trial. Rev Neurol (Paris), 169 : 737-743, 2013.

48) Doody RS, et al : A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med, 369 : 341-350, 2013.

49) Hasegawa H, et al : The FAM3 superfamily member ILEI ameliorates Alzheimer's disease-like pathology by destabilizing the penultimate amyloid-β precursor. Nat Commun, 5 : 3917 (doi : 10.1038/ncomms4917), 2014.

50) Norton S, et al : Potential for primary prevention of Alzheimer's disease : an analysis of population-based data. Lancet Neurol, 13 : 788-794, 2014.

51) 平野朝雄ほか : 神経病理を学ぶ人のために. 医学書院, 2003.

52) Pantoni L : Cerebral small vessel disease : from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol, 9 : 689-701, 2010.

53) 冨本秀和 : 血管性認知症の臨床と病理. Dementia Japan, 24 : 411-418, 2010.

54) Iadecola C : The pathology of vascular dementia. Neuron, 20 : 844-866, 2013.

55) Jellinger KA : Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci, 5 : 1-19, 2013.

56) Attems J, et al : The overlap between vascular disease and Alzheimer's disease-lessons from pathology. BMC Med, 12 : 206, 2014.

57) 上野正樹 : 血液脳関門の構造的特徴と生理機能. Dementia Japan, 29 : 36-43, 2015.

58) 伊丹裕一郎ほか : 血管性認知症における脳アミロイド血管症の位置づけ. Dementia Japan, 29 : 51-61, 2015.

59) Thal DR, et al : Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol, 115 : 599-609, 2008.

60) Weller RO, et al : Perivascular drainage of amyloid-β peptides from the brain and Its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol, 18 : 253-266, 2008.

61) Tournier-Lasserve E, et al : Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet 3 : 256-259, 1993.

62) Bowler JV, et al : Progress in the genetics of cerebrovascular disease : inherited subcortical arteriopathies. Stroke, 25 : 1696-1698, 1994.

63) Maeda S, et al : Familial unusual encephalopathy of Binswanger's type without hypertension. Folia Psychiatr Neurol Jpn, 30 : 165-177, 1976.

64) Fukutake T, et al : Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur Neurol, 35 : 69-79, 1995.

65) Yanagawa S, et al : Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Neurology, 58 : 817-820, 2002.

66) Joutel A, et al : Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature, 383 : 707-710, 1996.

67) 水野俊樹 : CADASILの診断, 病態, 治療の進歩-本邦におけるCADASIL診断基準の作成-. 臨神経, 52 : 303-313, 2012.

68) Hara K, et al : Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med, 360 : 1729-1739, 2009.

69) Nozaki K, et al : Features of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke, 45 : 3447-3453, 2015.

70) Goedert M, et al : 100 years of Lewy pathology. Nat Rev Neurol, 9 : 13-24, 2013.

71) 若林孝一 : レビー小体病における病変の拡大進展機構. Dementia Japan, 28 : 11-17, 2014.

72) 小阪憲司ほか : "Lewy 小体病" の臨床神経病理学的研究. 精神誌, 82 : 292-311, 1980.

73) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies. Neurology, 65 : 1863-1872, 2005.

74) Breydo L, et al : α-Synuclein misfolding and Parkinson's disease. Biochim Biophys Acta, 1822 : 261-285, 2012.

75) Polymeropoulos MH, et al : Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 276 : 2045-2047, 1997.

76) Fujiwara H, et al : alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol, 4 : 160-164, 2002.

77) Saito Y, et al : Accumulation of phosphorylated α-ｓynuclein in aging human brain. J Neuropathol Exp Neurol, 62 : 644-654, 2003.

78) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24 : 197-211, 2003.

79) Beach TG, et al : Unified staging system for Lewy body disorders : correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol, 117 : 613-634, 2009.

80) 池田学 : 前頭側頭型認知症. Dementia Japan, 29 : 121-122, 2015.

81) The Lund and Manchester Groups : Consensus Statement. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry, 4 : 416-418, 1994.

82) Snowden JS, Neary D, Mann DMA : Fronto-temporal lobar degeneration : fronto-temporal dementia, progressive aphasia, semantic dementia, Churchill Livingstone, New York, 1996.

83) Neary D, et al : Frontotemporal lobar degeneration : a consensus on clinical criteria. Neurology, 51 : 1546-1554, 1998.

84) 新井哲明ほか : 前頭側頭葉変性症の分子病理. Dementia Japan, 25 : 120-128, 2013.

85) 尾籠晃司ほか : 前頭側頭型認知症FTD (bvFTD) の新たな国際診断基準と問題点. Dementia Japan, 29 : 131-138, 2015.

86) 新井哲明 : タウオパチー病理変化の基礎. Dementia Japan, 29 : 158-166, 2015.

87) Arai T, et al : TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun, 351 : 602-611, 2006.

88) Neumann M, et al : Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314 : 130-133, 2006.

89) Neumana M, et al : A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain, 132 : 2922-2931, 2009.

90) Pelicano Paulos J, et al : Clinical, genetic and neuropathological features of frontotemporal dementia : an update and guide. Acta Med Port, 26 : 392-401, 2013.

91) Spillantini GM, et al : Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA, 95 : 7737-7741, 1998.

92) Hutton M, et al : Association of missense and 59-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 393 : 702-705, 1998.

93) Scheper W, et al : The unfolded protein response in neurodegenerative diseases : a neuropathological perspective. Acta Neuropathol, 130 : 315-331, 2015.

II 各論

P.36 掲載の参考文献

1) Swaab DF, et al : Biological rhythms in the human life cycle and their relationship to functional changes in the suprachiasmatic nucleus. Prog Brain Res, 111 : 349-368, 1996.

2) Mishima K, et al : Morning bright light therapy for sleep and behavior disorder in elderly patients with dementia. Acta Psychiatr Scand, 89 : 1-7, 1994.

3) Monk TH, et al : Circadian temperature rhythms of older people. Exp Gerontol, 30 : 455-474, 1995.

4) 財団法人健康・体力づくり事業団 : 健康づくりに関する意識調査報告, 1997.

5) Young T, et al : Predictors of sleep-disordered breathing in community-dwelling adults. The Sleep Heart Health Study. Arch Intern Med, 162 : 893-900, 2002.

6) Tsapanou A, et al : Daytime sleepiness and sleep inadequacy as risk factors for dementia. Dement Geratr Cogn Dis Extra, 5 : 286-295, 2015.

7) Merlino G, et al : Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults : a population-based study. Sleep Med, 11 : 372-377, 2010.

8) Benito-Leon J, et al : Long sleep duration in elders without dementia increases risk of dementia mortality (NEDICES). Neurology, 83 : 1530-1537, 2014.

9) Roh J, et al : Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. J Exp Med, 211 (13) : 2487-2496, 2014.

10) Lessig S, et al : Reduced Hypocretin (orexin) levels in dementia with lewy bodies. Neuroreport, 21 (11) : 756-760, 2010.

11) Coban A, et al : Reduced orexin-A levels in frontotemporal dementia : possible association with sleep disturbance. Am J Alzheimers Dis Other Demen, 28 (6) : 606-611, 2013.

12) Tractenberg RE, et al : Symptoms of sleep disturbance in persons with Alzheimer's disease and normal elderly. J Sleep Pres, 14 : 177-185, 2005.

13) McCurry S, et al : Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. J Geriatr Psychiatr Neurol, 12 : 53-59, 1999.

14) Pat-Horenczky R, et al : Hourly profiles of sleep and wakefulness in severely versus mild-moderately demented nursing home patients. Aging, 10 : 308-315, 1998.

15) Ancoli-Israel S, et al : Sleep fragmentation in patients in a nursing home. J Gerontol, 44 : M18-M21, 1989.

16) Riemersma-van der Lek RF, et al : Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities : a randomized controlled trial. JAMA, 299 : 2642-2655, 2008.

17) Bombois S, et al : Sleep disorders in aging and dementia. Nutr Health Aging, 14 : 212-217, 2010.

18) Vitiello MV, et al : Sleep disturbances in patients with Alzheimer's disease : epidemiololgy, pathophysiology and treatment. CNS Drugs, 15 : 777-796, 2001.

19) Moraes WS, et al : The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease : a double blind placebo-controlled study. Sleep, 29 : 199-205, 2006.

20) 千葉茂ほか : 認知症にみられる睡眠障害. 日認知症ケア会誌, 6 : 96-103, 2007.

21) Vitiello MV, et al : Circadian temperature rhythms in young adult and aged man. Neurobiol Aging, 7 : 97-100, 1986.

22) Zisapel N : Circadian rhythm sleep disorders : pathophysiology and potential approaches to management. CNS Drugs, 15 : 311-328, 2001.

23) Rose KM, et al : Sleep disturbances and nocturnal agitation behaviors in older adults with dementia. Sleep, 34 (6) : 779-786, 2011.

24) Rothdach AJ, et al : Prevelance and risk factors of RLS in elderly population ; the MEMO study. Memory and morbidity in Augsburg elderly. Neurology, 54 : 1064-1068, 2000.

25) Gamaldo CE, et al : A further evaluation of the cognitive deficits associated with restless legs syndrome (RLS). Sleep Med, 9 : 500-505, 2008.

26) Grace JB, et al : A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry, 15 : 1028-1033, 2000.

27) Schenck CH, et al : Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology, 46 : 388-393, 1996.

28) Terazaghi M, et al : Analysis of video-polysomnographic sleep findings in dementia with lewy bodies. Mov Disord, 28 (10) : 1416-1423, 2013.

29) Boeve BF, et al : Sinucleiopathy pathology and REM sleep behavior disorder plus dementia on parkinsonism. Neurology, 61 : 40-45, 2003.

30) Boeve BF, et al : Sinucleiopathy pathology and REM sleep behavior disorder plus dementia on parkinsonism. Neurology, 61 : 40-45, 2003.

31) Anderson KN, et al : Disrupted sleep and circadian patterns in frontotemporal dementia. Eur J Neurol, 16 : 317-323, 2009.

32) Harper DG, et al : Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. Arch Gen Psychiatry, 58 : 353-360, 2001.

P.42 掲載の参考文献

1) Bixler E, et al : Effects of age on sleep apnea in men : I. Prevalence and severity. Am J Respir Crit Care Med, 157 : 144-148, 1998.

2) American Academy of Sleep Medicine : International Classification of Sleep Disorders, 3rd ed, IL, 2014.

3) Sharafkhaneh A, et al : Association of psychiatric disorders and sleep apnea in a large cohort. Sleep, 28 : 1405-1411, 2005.

4) Yaffe K, et al : Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA, 306 : 613-619, 2011.

5) Chang WP, et al : Sleep apnea and the risk of dementia : a population-based 5-year follow-up study in Taiwan. PLoS One, 8 : 78655, 2013.

6) Aoki K, et al : Association of sleep-disordered breathing with decreased cognitive function among patients with dementia. J Sleep Res, 23 : 517-523, 2014.

7) Zimmerman ME, et al : Sleep-disordered breathing and cognition in older adults. Curr Neurol Neurosci Rep, 12 : 537-546, 2012.

8) Buratti L, et al : Vascular impairment in Alzheimer's disease : the role of obstructive sleep apnea. J Alzheimers Dis, 38 : 445-453, 2014.

9) Gelber RP, et al : Associations of brain lesions at autopsy with polysomnography features before death. Neurology, 84 : 296-303, 2015.

10) Kim H, et al : Obstructive sleep apnea as a risk factor for cerebral white matter change in a middle-aged and older general population. Sleep, 36 : 709-715B, 2013.

11) Canessa N, et al : Obstructive sleep apnea : brain structural changes and neurocognitive function before and after treatment. Am J Respir Crit Care Med, 183 : 1419-1426, 2011.

12) Macey PM : Is brain injury in obstructive sleep apnea reversible-Sleep, 35 : 9-10, 2012.

13) Thomas RJ, et al : Functional imaging of working memory in obstructive sleep-disordered breathing. J Appl Physiol, 98 : 2226-2234, 2005.

14) Elwood PC, et al : Sleep disturbance and daytime sleepiness predict vascular dementia. J Epidemiol Community Health, 65 : 820-824, 2011.

15) Kadotani H, et al : Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. JAMA, 285 : 2888-2890, 2001.

16) Osorio RS, et al : Sleep-disordered breathing advances cognitive decline in the elderly. Neurology, 84 : 1964-1971, 2015.

17) Weaver TE, et al : Adherence to continuous positive airway pressure therapy : the challenge to effective treatment. Proc Am Thorac Soc, 5 : 173-178, 2008.

18) Poulet C, et al : Psychological variables as predictors of adherence to treatment by continuous positive airway pressure. Sleep Med, 10 : 993-999, 2009.

P.50 掲載の参考文献

1) 総務省統計局 : 平成18年社会生活基本調査, 2006.

2) 白川修一郎 : 人間の睡眠・覚醒リズムと光 (心地よい眠りと目覚め). 照明学会誌, 84 : 354-361, 2000.

3) Walker JM, Berger RJ : Sleep as an adaptation for energy conservation functionally related to hibernation and shallow torpor. Prog Brain Res, 53 : 255-278, 1980.

4) 平沢秀人 : 高齢者の睡眠-小児から老人までの加齢変化. 日本睡眠学会 (編) : 36-41, 睡眠学ハンドブック, 朝倉書店, 1994.

5) 白川修一郎ほか : 高齢者の睡眠障害と心の健康. 精神保健研, 45 : 15-23, 1999.

6) Kim K, et al : An epidemiological study of insomnia among the Japanese general population. Sleep, 23 : 41-47, 2000.

7) 堀忠雄 : 睡眠習慣の実態調査と睡眠問題の発達的検討. 平成7年度～平成9年度文部科学省科学研究費補助金 (基盤研究 (A)) 研究成果報告書, 1998.

8) Bursztyn M, et al : Siesta and ambulatory blood pressure monitoring : comparability of the afternoon nap and night sleep. Am J Hypertens, 7 : 217-221, 1994.

9) Mulcahy D, et al : Heart rate and blood pressure consequences of an afternoon SIESTA (snooze-induced excitation of sympathetic triggered activity). Am J Cardiol, 71 : 611-614, 1993.

10) Asplund R : Daytime sleepiness and napping amongst the elderly in relation to somatic health and medical treatment. J Intern Med, 239 : 261-267, 1996.

11) Trichopoulos D, et al : Does a siesta protect from coronary heart disease-Lancet, 2 (8553) : 269-270, 1987.

12) Naska A, et al : Siesta in healthy adults and coronary mortality in the general population. Arc Intern Med, 167 : 296-301, 2007.

13) Bursztyn M, et al : The siesta and mortality in the elderly : effect of rest without sleep and daytime sleep duration. Sleep, 25 : 187-191, 2002.

14) Asada T, et al : Associations between retrospectively recalled napping behavior and later development of Alzheimer's disease : association with APOE genotypes. Sleep, 23 : 629-634, 2000.

15) 永田奈々恵ほか : プルスタグランジン, アデノシン : 86-90, 最新臨床睡眠学, 日本臨牀社, 2013.

16) Morin CM, et al : Nonpharmacologic treatment of chronic insomnia. Sleep, 22 : 1134-1156, 1999.

17) 白川修一郎ほか : 計画的昼寝の不眠高齢者に対する夜間睡眠改善効果. 臨脳波, 41 : 708-712, 1999.

18) 田中秀樹 : 高齢者への睡眠マネジメント. 白川修一郎, 高橋正也 (編) : 229-239, 睡眠マネジメント, NTS, 2014.

19) 林光緒 : 短時間仮眠による眠気の解消法. 日本睡眠改善協議会 (編) : 10-17, 応用講座睡眠改善学, ゆまに書房, 2013.

P.57 掲載の参考文献

1) Mishima K, et al : Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand, 89 (1) : 1-7, 1994.

2) 宮崎総一郎ほか : 睡眠障害. Pharma Tribune, 3 : 15-26, 2011.

3) Khalsa SB, et al : A phase response curve to single bright light pulses in human subjects. J Physiol, 549 : 945-952, 2003.

4) Cajochen C, et al : Dose-response relationship for light intensity and ocular and electroencephalographic correlates of human alertness. Behav Brain Res, 115 (1) : 75-83, 2000.

5) Zeitzer JM, et al : Sensitivity of the human circadian pacemaker to nocturnal light : melatonin phase resetting and suppression. J Physiol, 526 Pt 3 : 695-702, 2000.

6) Obayashi K, et al : Exposure to light at night, nocturnal urinary melatonin and obesity/dyslipidemia in the elderly : A cross sectional analysis of the HEIJYO-KYO Study. J Clin Endocrinal Metab, 98 : 337-344, 2013.

7) 大川匡子 : 高照度光療法. 日本臨, 73 : 997-1005, 2015.

8) Gooley JJ, et al : Spectral responses of the human circadian system depend on the irradiance and duration of exposure to light. Sci Transl Med, 2 (31) : 31ra33, 2010.

9) Okumoto Y, et al : Sleep improvement by light in a demented aged individual. Psychiatry Clin Neurosci, 52 : 194-196, 1998.

10) 翠川亨ほか : 高照度光照射が認知機能の低下を伴う高齢者の行動・心理症状と介護者負担へ及ぼす影響. 日老医誌, 51 : 184-190, 2014.

11) Sloane PD, et al : High-intensity environmental light in dementia : effect on sleep and activity. J Am Geriatr Soc, 55 (10) : 1524-1533, 2007.

12) Gammack JK : Light therapy for insomnia in older adults. Clin Geriatr Med, 24 (1) : 139-149, viii, 2008.

13) White MD, et al : Senior living environments : evidence-based lighting design strategies. HERD, 7 (1) : 60-78, 2013.

14) Lucas RJ, et al : Measuring and using light in the melanopsin age. Trends Neurosci, 37 (1) : 1-9, 2014.

P.63 掲載の参考文献

1) 厚生労働省 : 「認知症施策推進総合戦略～認知症高齢者等にやさしい地域づくりに向けて～ (新オレンジプラン)」について, 2015年1月27日報道発表資料 http://www.mhlw.go.jp/file/04-Houdouhappyou-12304500-Roukenkyoku-Ninchishougyakutaiboushitaisakusuishinshitsu/02_1.pdf

2) Kay DWK, et al : Old age mental disorders in Newcastle upon Tyne, II : a study of possible social and medical causes. Br J Psychiatry, 110 : 668-682, 1964.

3) Lin FR : Hearing loss and cognition among older adults in the United States. J Gerontol A Biol Sci Med Sci, 66 : 1131-1136, 2011.

4) Sugawara N, et al : Hearing impairment and cognitive function among a community-dwelling population in Japan. Ann Gen Psychiatry, 10 : 27, 2011.

5) Moore DR, et al : Relation between speech-in-noise threshold, hearing loss and cognition from 40-69 years of age. PLoS One, 9 : e107720, 2014.

6) Quaranta N, et al : The prevalence of peripheral and central hearing impairment and its relation to cognition in older adults. Audiol Neurootol, 19 Suppl 1 : 10-14, 2014.

7) Dawes P, et al : Hearing loss and cognition : the role of hearing aids, social isolation and depression. PLoS One, 10 : e0119616, 2015.

8) Harrison Bush AL, et al : Peripheral Hearing and Cognition : Evidence From the Staying Keen in Later Life (SKILL) Study. Ear Hear, 36 : 395-407, 2015.

9) Lin FR, et al : Hearing loss and incident dementia. Arch Neurol, 68 : 214-220, 2011.

10) Kiely KM, et al : Cognitive, health, and sociodemographic predictors of longitudinal decline in hearing acuity among older adults. J Gerontol A Biol Sci Med Sci, 67 : 997-1003, 2012.

11) Lin FR, et al : Association of hearing impairment with brain volume changes in older adults. Neuroimage, 90 : 84-92, 2014.

12) Gurgel RK, et al : Relationship of hearing loss and dementia : a prospective, population-based study. Otol Neurotol, 35 : 775-781, 2014.

13) Wayne RV, et al : A review of causal mechanisms underlying the link between age-related hearing loss and cognitive decline. Ageing Res Rev, 23 : 154-166, 2015.

14) Mulrow CD, et al : Quality-of-life changes and hearing impairment. A randomized trial. Ann Intern Med, 113 : 188-194, 1990.

15) van Hooren SA, et al : Does cognitive function in older adults with hearing impairment improve by hearing aid use-Int J Audiol, 44 : 265-271, 2005.

16) Dawes P, et al : Hearing-aid use and long-term health outcomes : Hearing handicap, mental health, social engagement, cognitive function, physical health, and mortality. Int J Audiol, 54 : 838-844, 2015.

17) Mosnier I, et al : Improvement of cognitive function after cochlear implantation in elderly patients. JAMA Otolaryngol Head Neck Surg, 141 : 442-450, 2015.

18) 杉浦彩子ほか : 認知機能障害のある難聴高齢者に対する補聴器適合. Audiol Jpn, 58 : 81-87, 2015.

19) Meister H, et al : Hearing aid fitting in older persons with hearing impairment : the influence of cognitive function, age, and hearing loss on hearing aid benefit. Clin Interv Aging, 10 : 435-443, 2015.

20) 内田育恵ほか : 全国高齢難聴者数推計と10年後の年齢別難聴発症率老化に関する長期縦断疫学研究 (NILS-LSA) より. 日老医誌, 49 : 222-227, 2012.

P.68 掲載の参考文献

1) Dayawansa S, et al : Autonomic responses during inhalation of natural fragrance of "Cedrol" in humans. Auton Neurosci, 108 : 79-86, 2003.

2) Carskadon MA, et al : Minimal olfactory perception during sleep : why odor alarms will not work for humans. Sleep, 27 : 402-405, 2004.

3) Hardy M, et al : Replacement of drug treatment for insomnia by ambient odour. Lancet, 346 : 701, 1995.

4) Lewith GT, et al : A single-blinded, randomized pilot study evaluating the aroma of Lavandula augustifolia as a treatment for mild insomnia. J Altern Complement Med, 11 : 631-637, 2005.

5) 山本由華吏ほか : 香気成分セドロールが睡眠に及ぼす影響. 日本生理人類会誌, 8 : 69-73, 2003.

6) Yamagishi R, et al : Sleep-improving effects of the aromatic compound heliotropin. Sleep and Biol Rhythms, 8 : 254-260, 2010.

7) Ballard CG, et al : Aromatherapy as a safe an effective treatment for the management of agitation in severe dementia : the results of a double-blind placebo-controlled trial with Melissa. J Clin Psychiatry, 63 : 553-558, 2002.

8) Lin PW, et al : Efficacy of aromatherapy (Lavandula angustifolia) as an intervention for agitated behaviours in Chinese older persons with dementia : a cross-over randomized trial. Int J Geriatr Psychiatry, 22 : 405-410, 2007.

9) Thorgrimsen L, et al : Aroma therapy for dementia. Cochrane Database Syst Rev CD003150, 2003.

10) Norrish MI, et al : Preliminary investigation of the effect of peppermint oil on an objective measure of daytime sleepiness. Int J Psychophysiol, 55 : 291-298, 2005.

11) 大川匡子 : 加齢と生体リズム-痴呆老年者の睡眠リズム異常とその新しい治療-. 神経進歩, 36 : 102-111, 1992.

12) Kryscio RJ, et al : Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology, 66 : 828-832, 2006.

13) Ju Y-ES, et al : Sleep quality and preclinical Alzheimer Disease. JAMA Neurol, 70 (5) : 587-593, 2013.

III 診断

P.77 掲載の参考文献

1) 浦上克哉 : 痴呆症の治療意義と適切なケアについて-主治医意見書のポイントを含めて-. 癌と化学療法, 30 : 49-53, 2003.

2) 浦上克哉ほか : アルツハイマー型痴呆の遺伝子多型と簡易スクリーニング法. 老年精医誌, 13 : 5-10, 2002.

3) Petersen RC, et al : Mild cognitive impairment : Clinical characterization and outcome. Arch Neurol, 56 : 303-308, 1999.

4) 浦上克哉 : 認知症の神経学的所見のとり方. 本間昭 (編) : 45-49, 臨床医のためのアルツハイマー型認知症実践診療ガイド. じほう, 2006.

5) Bruni AC, et al : Heterogeneity within a large kindred with frontotemporal dementia ; A novel progranulin mutation. Neurology, 69 : 140-147, 2007.

6) Taniguchi M, et al : Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease. Dement Geriatr Cogn Disord, 26 : 117-122, 2008.

P.83 掲載の参考文献

1) Gottfried J, et al : Smell : Central nervous processing. Hummel T, et al eds : 44-69, Adv Otorhinolaryngol. Karger, 2006.

2) Miwa T, et al : Role of nerve growth factor in the olfactory system. Microsc Res Tech, 58 : 197-203, 2002.

3) Doty RL, et al : Smell identification ability ; changes with age. Science, 226 : 1441-1442, 1984.

4) Saito S, et al : Development of a smell identification test using a novel stick-type odor presentation kit. Chem Sences, 31 : 379-391, 2006.

5) Hoffman HJ, et al : Age-related changes in the prevalence of smell/taste problems among the United States adult population. Results of the 1994 disability supplement to the National Health Interview Survey (NHIS). Ann N Y Acad Sci, 855 : 716-722, 1998.

6) Cain WS, et al : Clinical evaluation of olfaction. Am J Otolaryngol, 4 : 252-256, 1983.

7) Hummel T, et al : Normative data for the "Sniffin' Sticks" including tests of odor identification, odor discrimination, and olfactory thresholds : an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol, 264 : 237-243, 2007.

8) 三輪高喜ほか : 嗅覚障害患者を対象としたスティック型嗅覚検査法の臨床的有用性に関する研究. 日耳鼻会誌, 107 : 956-965, 2004.

9) Kobayashi M, et al : Suitability of the odor stick identification test for the Japanese in patients suffering from olfactory disturbance. Acta Otolaryngol Suppl, 553 : 74-79, 2004.

10) 志賀英明ほか : 人間ドックにおけるスティック型嗅覚検査法 (OSIT) による嗅覚障害スクリーニングの検討. 日耳鼻会誌, 110 : 586-591, 2007.

11) 西田幸平ほか : カード型嗅覚同定検査「Open Essence」の有用性. 日耳鼻会誌, 113 : 751-757, 2010.

12) Okutani F, et al : Evaluation of "Open Essence" odor-identification test card by application to healthy volunteers. Auris Nasus Larynx, 40 : 76-80, 2013.

13) Fujio H, et al : Evaluation of card-type odor identification test for Japanese patients with olfactory disturbance. Ann Otol Rhinol Laryngol, 121 : 413-418, 2012.

14) Devanand DP, et al : Combining early markers strongly predicts conversion from MCI to AD. Biol Psychiatry, 64 : 871-879, 2008.

15) Pfeffer RI, et al : Measurement of functional activities in older adults in the community. J Gerontol, 37 : 323-329, 1982.

P.91 掲載の参考文献

1) Doty RL, et al : Development of the University of Pennsylvania Smell Identification Test : a standardized microencapsulated test of olfactory function. Physiol Behav, 32 (3) : 489-502, 1984. (PubMed PMID : 6463130)

2) Godoy MD, et al : Olfaction in neurologic and neurodegenerative diseases : a literature review. Int Arch Otorhinolaryngol, 19 (2) : 176-179, 2015. (doi : 10.1055/s-0034-1390136. Epub 2014 Nov 14. PubMed PMID : 25992176 ; PubMed Central PMCID : PMC4399182)

3) Attems J, et al : Olfaction and Aging : A Mini-Review. Gerontology, 61 (6) : 4854-4890, 2015. (doi : 10.1159/000381619. Epub 2015 May 9. PubMed PMID : 25968962)

4) Ruan Y, et al : Olfactory dysfunctions in neurodegenerative disorders. J Neurosci Res, 90 (9) : 1693-1700, 2012. (doi : 10.1002/jnr. 23054. Epub 2012 Jun 5. Review. PubMed PMID : 22674288)

5) Bitter T, et al : Anosmia leads to a loss of gray matter in cortical brain areas. Chem Senses, 35 (5) : 407-415, 2010. (doi : 10.1093/chemse/bjq028. Epub 2010 Mar 15. PubMed PMID : 20231262)

6) Growdon ME, et al : Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology, 84 (21) : 2153-2160, 2015. (doi : 10.1212/WNL. 0000000000001614. Epub 2015 May 1. PubMed PMID : 25934852 ; PubMed Central PMCID : PMC4451046)

7) Mesholam RI, et al : Olfaction in neurodegenerative disease : a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol, 55 (1) : 84-90, 1998. (PubMed PMID : 9443714)

8) Bahar-Fuchs A, et al : Awareness of olfactory deficits in healthy aging, amnestic mild cognitive impairment and Alzheimer's disease. Int Psychogeriatr, 23 (7) : 1097-1106, 2011. (doi : 10.1017/S1041610210002371. Epub 2011 Jan 21. PubMed PMID : 21251352)

9) Averback P : Two new lesions in Alzheimer's disease. Lancet, 2 (8360) : 1203, 1983. (PubMed PMID : 6139562)

10) Serby M, et al : The nature and course of olfactory deficits in Alzheimer's disease. Am J Psychiatry, 148 (3) : 357-360, 1991. (PubMed PMID : 1992839)

11) Sperling RA, et al : Toward defining the preclinical stages of Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 7 (3) : 280-292, 2011. (doi : 10.1016/j. jalz. 2011.03.003. Epub 2011 Apr 21. PubMed PMID : 21514248 ; PubMedCentral PMCID : PMC3220946)

12) Huttenbrink KB, et al : Olfactory dysfunction : common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int, 110 (1-2) : 1-7, 2013. (e1. doi : 10.3238/arztebl. 2013.0001. Epub 2013 Jan 7. Review. PubMed PMID : 23450985 ; PubMed Central PMCID : PMC3561743)

13) Devanand DP, et al : Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry, 157 (9) : 1399-1405, 2000. (PubMed PMID : 10964854)

14) Graves AB, et al : Impaired olfaction as a marker for cognitive decline : interaction with apolipoprotein E epsilon4 status. Neurology, 53 (7) : 1480-1487, 1999. (PubMed PMID : 10534255)

15) Growdon ME, et al : Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology, 84 (21) : 2153-2160, 2015. (doi : 10.1212/WNL. 0000000000001614. Epub 2015 May 1. PubMed PMID : 25934852 ; PubMed Central PMCID : PMC4451046)

16) Wilson RS, et al : The relationship between cerebral Alzheimer's disease pathology and odour identification in old age. J Neurol Neurosurg Psychiatry, 78 (1) : 30-35, 2007. (Epub 2006 Sep 29. PubMed PMID : 17012338 ; PubMed Central PMCID : PMC2117790)

17) Braak H, et al : Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol, 82 (4) : 239-259, 1991. (Review. PubMed PMID : 1759558)

18) Kovacs T, et al : Olfactory centres in Alzheimer's disease : olfactory bulb is involved in early Braak's stages. Neuroreport, 12 (2) : 285-288, 2001. (PubMed PMID : 11209936)

19) Schubert CR, et al : Olfaction and the 5-year incidence of cognitive impairment in an epidemiological study of older adults. J Am Geriatr Soc, 56 (8) : 1517-1521, 2008. (doi : 10.1111/j. 1532-5415.2008.01826. x. Epub 2008 Jul 24. PubMed PMID : 18662205 ; PubMed Central PMCID : PMC2587240)

20) Swan GE, et al : Impaired olfaction predicts cognitive decline in nondemented older adults. Neuroepidemiology, 21 (2) : 58-67, 2002. (PubMed PMID : 11901274)

21) Wilson RS, et al : Odor identification and decline in different cognitive domains in old age. Neuroepidemiology, 26 (2) : 61-67, 2006. (Epub 2005 Dec 13. PubMed PMID : 16352908)

22) Devanand DP, et al : Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry, 64 (10) : 871-879, 2008. (doi : 10.1016/j. biopsych. 2008.06.020. Epub 2008 Aug 23. PubMed PMID : 18723162 ; PubMed Central PMCID : PMC2613777)

23) Devanand DP, et al : Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology, 84 (2) : 182-189, 2015. (doi : 10.1212/WNL. 0000000000001132. Epub 2014 Dec 3. PubMed PMID : 25471394 ; PubMed Central PMCID : PMC4336090)

24) Roberts RO, et al : Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia. JAMA Neurol, 73 (1) : 93-101, 2016. (doi : 10.1001/jamaneurol. 2015.2952. PubMed PMID : 26569387 ; PubMed Central PMCID : PMC4710557)

25) Ansari KA, et al : Olfactory function in patients with Parkinson's disease. J Chronic Dis, 28 (9) : 493-497, 1975. (PubMed PMID : 1176578)

26) Doty RL, et al : Olfactory dysfunction in parkinsonism : a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology, 38 (8) : 1237-1244, 1988. (PubMed PMID : 3399075)

27) Hawkes CH, et al : Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry, 62 (5) : 436-446, 1997. (PubMed PMID : 9153598 ; PubMed Central PMCID : PMC486843)

28) Boesveldt S, et al : A comparative study of odor identification and odor discrimination deficits in Parkinson's disease. Mov Disord, 23 (14) : 1984-1990, 2008. (doi : 10.1002/mds. 22155. PubMed PMID : 18759360)

29) Hawkes C : Olfaction in neurodegenerative disorder. Mov Disord, 18 (4) : 364-372, 2003. (Review. PubMed PMID : 12671941)

30) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24 (2) : 197-211, 2003. (PubMed PMID : 12498954)

31) Ponsen MM, et al : Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol, 56 (2) : 173-181, 2004. (PubMed PMID : 15293269)

32) Baba T, et al : Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease : a 3 year longitudinal study. Brain, 135 (Pt 1) : 161-169, 2012. (doi : 10.1093/brain/awr321. PubMed PMID : 22287381)

33) McShane RH, et al : Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology. J Neurol Neurosurg Psychiatry, 70 (6) : 739-743, 2001. (PubMed PMID : 11385006 ; PubMed Central PMCID : PMC1737382)

34) Wilson RS, et al : Lewy bodies and olfactory dysfunction in old age. Chem Senses, 36 (4) : 367-373, 2011. (doi : 10.1093/chemse/bjq139. Epub 2011 Jan 21. PubMed PMID : 21257733 ; PubMed CentralPMCID : PMC3073534)

35) Fujishiro H, et al : Dementia with Lewy bodies : early diagnostic challenges. Psychogeriatrics, 13 (2) : 128-138, 2013. (doi : 10.1111/psyg. 12005. Review. PubMed PMID : 23909972)

36) Yoon JH, et al : Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment : A 5-year follow-up study. J Neurol Sci, 355 (1-2) : 174-179, 2015. (doi : 10.1016/j. jns. 2015.06.013. Epub 2015 Jun 10. PubMed PMID : 26076880)

37) Donaghy PC, et al : The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther, 6 (4) : 46, 2014. (doi : 10.1186/alzrt274. eCollection 2014. Review. PubMed PMID : 25484925 ; PubMed Central PMCID : PMC4255387)

38) Schenck CH, et al : Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder : a 16-year update on a previously reported series. Sleep Med, 14 (8) : 744-748, 2013. (doi : 10.1016/j. sleep. 2012.10.009. Epub 2013 Jan 22. PubMed PMID : 23347909)

39) Postuma RB, et al : Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology, 72 (15) : 1296-1300, 2009. (doi : 10.1212/01. wnl. 0000340980.19702.6e. Epub 2008 Dec 24. PubMed PMID : 19109537 ; PubMed Central PMCID : PMC2828948)

40) Iranzo A, et al : Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder : a descriptive study. Lancet Neurol, 5 (7) : 572-577, 2006. (PubMed PMID : 16781987)

41) Uchiyama M, et al : Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology, 45 (4) : 709-712, 1995. (PubMed PMID : 7723959)

42) Boeve BF, et al : Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med, 14 (8) : 754-762, 2013. (doi : 10.1016/j. sleep. 2012.10.015. Epub 2013 Mar 7. PubMed PMID : 23474058 ; PubMed Central PMCID : PMC3745815)

43) Iranzo A, et al : Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder : an observational cohort study. Lancet Neurol, 12 (5) : 443-453, 2013. (doi : 10.1016/S1474-4422 (13) 70056-5. Epub 2013 Apr 3. PubMed PMID : 23562390)

44) Stiasny-Kolster K, et al : Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain, 128 (Pt 1) : 126-137, 2005. (Epub 2004 Nov 17. PubMed PMID : 15548552)

45) Fantini ML, et al : Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull, 70 (4-6) : 386-390, 2006. (Epub 2006 Aug 7. PubMed PMID : 17027774)

46) Miyamoto T, et al : Olfactory dysfunction in idiopathic REM sleep behavior disorder. Sleep Med, 11 (5) : 458-461, 2010. (doi : 10.1016/j. sleep. 2009.09.013. Epub 2010 Apr 7. PubMed PMID : 20378403)

47) Iwanami M, et al : Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. Sleep Med, 11 (4) : 361-365, 2010. (doi : 10.1016/j. sleep. 2009.12.006. PubMed PMID : 20223708)

48) Miyamoto T, et al : Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology, 67 (12) : 2236-2238, 2006. (PubMed PMID : 17190953)

49) 宮本雅之ほか : レム睡眠行動異常症と神経変性疾患. 日本医事新報, 4415 : 57-64, 2008.

50) Mahlknecht P, et al ; Sleep Innsbruck Barcelona Group : Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology, 84 (7) : 654-658, 2015. (doi : 10.1212/WNL. 0000000000001265. Epub 2015 Jan 21. PubMed PMID : 25609758)

P.100 掲載の参考文献

1) Hook EW 3rd, et al : Acquired syphilis in adults. N Engl J Med, 16 : 1060-1069, 1992.

2) Portegies P, et al : Presentation and course of AIDS dementia complex : 10 years of follow-up in Amsterdam, The Netherlands. AIDS, 7 : 669-675, 1993.

3) Brew BJ, et al : Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis, 175 : 963-966, 1997.

4) Selhub J, et al : Association between plasma homocysteine concentrations and extracranial carotid-artery atenosis. N Engl J Med, 332 : 286-291, 1995.

5) Bostom AG, et al : Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons : the Framingham Study. Ann Intern Med, 131 : 352-355, 1999.

6) Seshadri S, et al : Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med, 346 : 476-483, 2002.

7) Gudala K, et al : Diabetes mellitus and risk of dementia : A meta-analysis of prospective observational studies. J Diabetes Investig, 4 : 640-650, 2013.

8) Cheng G, et al : Diabetes as a risk factor for dementia and mild cognitive impairment : a meta-analysis of longitudinal studies. Intern Med J, 42 : 484-491, 2012.

9) Biesseis GJ, et al : Risk of dementia in diabetes mellitus : a systematic review. Lancet Neurol, 5 : 64-74, 2006.

10) Fukazawa R, et al : Subgroups of Alzheimer's disease associated with diabetes mellitus based on brain imaging. Dement Geriatr Cogn Disord, 35 : 280-290, 2013.

11) Kivipelto M, et al : Midlife vascular risk factors and Alzheimer's disease in later life : longitudinal, population-based study. BMJ, 322 : 1447-1451, 2001.

12) Haag MD, et al : Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry, 80 : 13-17, 2009.

13) Thacker EL, et al : Atrial fibrillation and cognitive decline : a longitudinal cohort study. Neurology, 81 : 119-125, 2013.

14) Park-Wyllie LY, et al : Cholinesterase inhibitors and hospitalization for bradycardia : a population-based study. PLoS Med, 6 : e1000157, 2009.

15) Ramsay RE, et al : Special considerations in treating the elderly patient with epilepsy. Neurology, 62 : S24-29, 2004.

16) Granger N, et al : First epileptic seizure in the elderly : electroclinical and etiological data in 341 patients. Rev Neurol (Paris), 158 : 1088-1095, 2002.

17) Mendez M, et al : Seizures in elderly patients with dementia : epidemiology and management. Drugs Aging, 20 : 791-803, 2003.

18) Bennett SA, et al : Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging, 21 : 207-214, 2000.

19) Stefani A, et al : CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia. J Neurol Sci, 283 : 109-115, 2009.

20) Hughes TM, et al : Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults. Neurology, 81 : 1711-1718, 2013.

21) Dede DS, et al : Assessment of endothelial function in Alzheimer's disease : is Alzheimer's disease a vascular disease-J Am Geriatr Soc, 55 : 1613-1617, 2007.

22) Williams SS, et al : Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease. J Neurol Neurosurg Psychiatry, 80 : 667-670, 2009.

23) Jimbo D, et al : Specific feature of olfactory dysfunction with Alzheimer's disease inspected by the Odor Stick Identification Test. Psychogeriatrics, 11 : 196-204, 2011.

P.106 掲載の参考文献

1) Tanaka S, et al : Tissue-specific expression of three types of β-protein precursor mRNA : enhancement of protease inhibitor-harboring types in Alzheimer's disease brain. Biochem Biophys Res Commun, 165 (3) : 1406-1414, 1989.

2) Guo Q, et al : APP physiological and pathophysiological functions : insights from animal models. Cell Res, 22 (1) : 78-89, 2012.

3) Asai M, et al : Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun, 301 (1) : 231-235, 2003.

4) Vassar R, et al : Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286 (5440) : 735-741, 1999.

5) Yu G, et al : Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature, 407 (6800) : 48-54, 2000.

6) Francis R, et al : aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell, 3 (1) : 85-97, 2002.

7) Younkin SG, et al : Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann Neurol, 37 (3) : 287-288, 1995.

8) Selkoe DJ, et al : Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 399 (6738 Suppl) : A23-31, 1999.

9) Bitan G, et al : Amyloid beta-protein (Abeta) assembly : Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A, 100 (1) : 330-335, 2003.

10) Liang F, et al : Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease. J Clin Neurosci, 20 (3) : 357-361, 2013.

11) Deane R, et al : RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med, 9 (7) : 907-913, 2003.

12) Bateman RJ, et al : Fluctuations of CSF amyloid-beta levels : implications for a diagnostic and therapeutic biomarker. Neurology, 68 (9) : 666-669, 2007.

13) Huang Y, et al : Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol, 69 (1) : 51-58, 2012.

14) Jakes R, et al : Identification of 3-and 4-repeat tau isoforms within the PHF in Alzheimer's disease. EMBO J, 10 (10) : 2725-2729, 1991.

15) Bronner IF, et al : Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. Brain, 128 (Pt 11) : 2645-2653, 2005.

16) Chambers CB, et al : Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol, 46 (3) : 325-332, 1999.

17) Takanashi M, et al : Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Brain Res Mol Brain Res, 104 (2) : 210-219, 2002.

18) Hardy J, et al : The amyloid hypothesis of Alzheimer's disease : progress and problems on the road to therapeutics. Science, 297 (5580) : 353-356, 2002.

19) Magnoni S, et al : Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain, 135 (Pt 4) : 1268-1280, 2012.

20) Hesse C, et al : Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett, 297 (3) : 187-190, 2001.

21) Otto M, et al : Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett, 225 (3) : 210-212, 1997.

22) Jin K, et al : CSF tau protein : a new prognostic marker for Guillain-Barre syndrome. Neurology, 67 (8) : 1470-1472, 2006.

23) Kapaki E, et al : Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol, 43 (4) : 228-232, 2000.

24) Hampel H, et al : Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease : a comparative cerebrospinal fluid study. Arch Gen Psychiatry, 61 (1) : 95-102, 2004.

IV 治療

P.112 掲載の参考文献

1) 浦上克哉 : これでわかる認知症診療～改訂第2版～. 南江堂, 2012.

2) Inoue M, et al : Touch panel-type dementia assessment scale : A new computer-based rating scale for Alzheimer's disease. Psychogeriatrics, 11 : 28-33, 2011.

3) Jimbo D, et al : Effect of aromatherapy on patients with Alzheimer's disease. Psychogeriatrics, 9 : 173-179, 2009.

4) Taniguchi M, et al : Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease. Dement Geriatr Cogn Disord, 26 : 117-122, 2008.

P.119 掲載の参考文献

1) Montgomery P, et al : A systematic review of non-pharmacological therapies for sleep problems in later life. Sleep Medicine Reviews, 8 : 47-62, 2004.

2) Bliwise DL : Normal aging. Kryger MH, et al (eds) : 26-39, Principles and practice of sleep medicine, 3rd ed, WB Saunders, 2000.

3) Stopa EG, et al : Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol, 58 : 29-39, 1999.

4) Liu RY, et al : Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol, 59 : 314-322, 2000.

5) 白川修一郎ほか : 高齢社会日本の課題と展望. 田中秀樹 (編) : 3-22, 高齢期の心を活かす. ゆまに書房, 2006.

6) Tanaka H, et al : Sleep health, lifestyle and mental health in the Japanese elderly-Ensuring sleep to promote a healthy brain and mind-. J Psychosom Res, 56 : 465-477, 2004.

7) 田中秀樹ほか : 高齢者の意欲的なライフスタイルと睡眠生活習慣についての検討. 老年精医誌, 7 : 1345-1350, 1996.

8) Stokkan KA, et al : Entrainment of the circadian clock in the liver by feeding. Science, 291 : 490-493, 2001.

9) 田中秀樹ほか : 地域高齢者の睡眠障害改善のための非薬物アプローチ. 睡眠医療, 6 : 559-568, 2012.

10) Tanaka H, et al : Sleep management promotes healthy lifestyle, mental health, QOL, and a healthy brain. Jinglong Wu (ed) : 211-224, Biomedical Engineering and Cognitive Neuroscience for Healthcare : Interdisciplinary Application, IGI Global, Hershey, 2012.

11) 田中秀樹 : 望ましい睡眠環境と夏期, 冬季の対応-連載転倒予防・QOL向上に向けた睡眠障害改善-. 通所介護リハ, 8 (4) : 75-79, 2010.

12) 田中秀樹 : 地域高齢者の睡眠改善のための介入技法と評価法. 日本睡眠改善協議会 (編) : 148-162, 応用講座睡眠改善学, ゆまに書房, 2013.

13) Asada T, et al : Associations between retrospectively recalled napping behavior and later development of Alzheimer's disease : association with APOE genotypes. Sleep, 23 : 629-634, 2000.

14) Mishima K, et al : Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J Clin Endocrinol Metab, 86 (1) : 129-134, 2001.

15) 田中秀樹, 荒川雅志 : 認知症, 転倒予防のための快眠術, 短い昼寝と夕方の福寿体操のススメ. 東京法規出版, 2005.

16) Tanaka H, et al : Short nap and exercise improve sleep quality and mental health in the elderly. Psychiatry Clin Neurosc, 56 : 233-234, 2002.

17) Atkinson G, et al : Circadian variation in sports performance. Sports Med, 21 : 292-312, 1996.

18) 田中秀樹 (編著) : 高齢期の心を活かす-衣・食・住・遊・眠・美と認知症・介護予防-. ゆまに書房, 2006.

19) 田中秀樹 : 睡眠確保からの脳とこころのヘルスプロモーション, 睡眠・ライフスタイルと脳・心身の健康. 地域保健, 6 : 5-26, 2002.

20) 田中秀樹 : 快適睡眠と生活習慣病, 痴呆予防. 小西美智子ほか (編) : 90-135, 介護ハンドブック. 関西看護出版, 2002.

21) 田中秀樹 : ぐっすり眠れる3つの習慣. KKベストセラーズ, 2008.

22) 田村典久ほか : 高齢者への自己調整法を用いたスリープマネジメントが睡眠, QOL, 自己効力感に与える効果. 広島国際大学心理臨床センター紀要, 12 : 19-34, 2013.

23) Tanaka H, et al : Sleep education with self-help treatment and sleep health promotion for mental and physical wellness in Japan. Sleep Biol Rhythms. Publish online, DOI 10.1007/s41105-015-0018-6, 2015.

24) 田村典久ほか : 重度の睡眠障害をもつ地域高齢者に対する快眠教室が, 不眠, 日中の眠気, QOLの改善に与える効果. こころの健康, 3 (2) : 28-39, 2015.

25) 堀忠雄 (編) : 睡眠心理学. 北大路書房, 2007.

P.126 掲載の参考文献

1) 中村祐 : アルツハイマー型認知症治療薬の使い分けは可能か. 老年精医誌, 23 (9) : 1027-1036, 2012.

2) 長田乾ほか : NMDA 受容体拮抗薬メマンチンの薬理作用とアルツハイマー病における臨床効果. 脳21, 15 (4) : 474-486, 2012.

3) Nakamura Y, et al : A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra, 1 (1) : 163-179, 2011.

4) Howard R, et al : Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med, 366 (10) : 893-903, 2012.

5) 中村祐 : アルツハイマー病の中核症状治療メマンチン. Brain Med, 25 (1) : 15-22, 2013.

6) 東海林幹夫 : アルツハイマー病の中核症状治療抗コリンエステラーゼ薬ドネペジル, ガランタミン, リバスチグミン. Brain Med, 25 (1) : 7-13, 2013.

7) 遠藤英俊 : 臨床に役立つ Q&A 認知症の薬の副作用で気をつけることを教えてください. Geriatr Med, 51 (1) : 75-77, 2013.

8) 「認知症疾患治療ガイドライン」作成合同委員会 : 認知症疾患治療ガイドライン 2010, 医学書院, 2010.

9) Burns A, et al : Efficacy and safety of donepezil over 3 years : an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry, 22 (8) : 806-812, 2007.

10) Doody RS, et al : Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol, 58 (3) : 427-433, 2001.

11) 堀宏治ほか : アルツハイマー病の認知機能改善薬と根本治療薬ドネペジル長期投与のエビデンス. 治療, 93 (9) : 1874-1877, 2011.

12) 中村祐 : 薬物療法と長期経過・予後. 老年精医誌, 20 (6) : 630-639, 2009.

13) Nakano S, et al : Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med, 42 (10) : 1441-1445, 2001.

14) Rogers SL, et al : Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease : final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol, 10 (3) : 195-203, 2000.

15) Winblad B, et al : 3-year study of donepezil therapy in Alzheimer's disease : effects of early and continuous therapy. Dement Geriatr Cogn Disord, 21 (5-6) : 353-363, 2006.

16) 本間昭ほか : ガランタミン臭化水素酸塩のアルツハイマー型認知症に対するプラセボ対照二重盲検比較試験. 老年精医誌, 22 (3) : 333-345, 2011.

17) Raskind MA, et al : The cognitive benefits of galantamine are sustained for at least 36 months : a long-term extension trial. Arch Neurol, 61 (2) : 252-256, 2004.

18) Bullock R, et al : Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin, 21 (8) : 1317-1327, 2005.

19) Doraiswamy PM, et al : Long-term effects of rivastigmine in moderately severe Alzheimer's disease : does early initiation of therapy offer sustained benefits-Prog Neuropsychopharmacol Biol Psychiatry, 26 (4) : 705-712, 2002.

20) 片山禎夫 : リバスチグミンの使用経験第III相二重盲検・長期試験の経験から. 老年精医誌, 23 (9) : 1096-1101, 2012.

21) Homma A, et al : Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease : results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord, 27 (3) : 232-239, 2009.

22) Tariot PN, et al : Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil : a randomized controlled trial. JAMA, 291 (3) : 317-324, 2004.

23) 丸木雄一 : アルツハイマー病の認知機能改善薬と根本治療薬ドネペジルの副作用への対応. 治療, 93 (9) : 1857-1861, 2011.

24) 山崎峰雄 : 認知症の薬物治療の工夫服薬コンプライアンスをあげるために. 治療, 93 (9) : 1835-1838, 2011.

25) 山村恵子ほか : アルツハイマー型認知症治療薬の副作用管理アドヒアランス向上を目指した副作用説明のポイント. 薬局, 63 (2) : 285-291, 2012.

26) FDA Talk Paper (http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS0153.html)

27) 堀口淳 : 今日の治療指針 2015年版. 医学書院, 2015.

P.136 掲載の参考文献

1) Sperling RA, et al : Toward defining the preclinical stages of Alzheimer's disease. Alzheimers Dement, 7 : 280-292, 2011.

2) Williams SCP : Mapping the brain's decline. Nature, 502 : s84-85, 2013.

3) 西野仁雄 : 手をよく使うと心が開かれる NPO法人健康な脳づくり (編) : 71-98, 認知症にならないために. ゆいぽおと, 2014.

4) 西野仁雄 : 死ぬまでボケない10の習慣. PHP文庫, 2012.

5) Penfield W, et al : The Cerebral Cortex of Man : A Clinical Study of Localization of Function, Hafner, 1968.

6) 山内智之ほか : ポリエチレン繊維からなるクッショングリップを持続的に握ると脳梗塞後の手の拘縮および筋緊張が速やかに改善される. 日生理誌, S150, 2013.

7) 西野仁雄 : ミラクルグリップ. 文藝春秋, 2015.

8) Nishino H, et al : Contracture of finger and hand and disturbance in speech after stroke were improved in a short duration by grasping a high repulsion cushion grip. J Neurosci and Neuroengineer, 4 : 1-8, 2015.

9) 白木基之ほか : 3-D高反発力クッション上での足踏みは前頭葉の血流を増加させる. 日生理誌, S227, 2013.

10) Rosenzweig MR, et al : Brain changes in response to experience. Sci Amer, 226 : 22-30, 1972.

11) Volkmar FR, et al : Rearing complexity affects branching of dendrites in the visual cortex of rat. Science, 176 : 1445-1447, 1972.

12) Urakawa S, et al : Environmental enrichment brings a beneficial effect on beam walking and enhances the migration of doublecortin-positive cells following striatal lesions in rats. Neuroscience, 144 : 920-933, 2007.

13) Horstman J : Healthy Aging Brain. Sci Amer, 2012.

14) Zimmer C : シミュレーションで解く脳の複雑性. 日経サイエンス, 4 : 73-78, 2011.

P.143 掲載の参考文献

1) Ueda K, et al : Effects of functional training of dysphagia to prevent pneumonia for patients on tube feeding. Gerodontology, 21 : 108-111, 2004.

2) 植田耕一郎 : 歯科が実施する摂食嚥下リハビリテーション. 日摂食嚥下リハ会誌, 18 (3) : 205-220, 2014.

書評

書評を投稿する

最近チェックした商品履歴

Loading...